- Home
- PRAX vs TIXT Comparison
PRAX vs TIXT Comparison
Compare PRAX & TIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- TIXT
- Stock Information
- Founded
- PRAX 2015
- TIXT 2005
- Country
- PRAX United States
- TIXT Canada
- Employees
- PRAX N/A
- TIXT N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- TIXT EDP Services
- Sector
- PRAX Health Care
- TIXT Technology
- Exchange
- PRAX Nasdaq
- TIXT Nasdaq
- Market Cap
- PRAX 950.8M
- TIXT 1.0B
- IPO Year
- PRAX 2020
- TIXT 2021
- Fundamental
- Price
- PRAX $47.08
- TIXT $3.84
- Analyst Decision
- PRAX Strong Buy
- TIXT Hold
- Analyst Count
- PRAX 10
- TIXT 9
- Target Price
- PRAX $102.00
- TIXT $3.77
- AVG Volume (30 Days)
- PRAX 578.2K
- TIXT 731.8K
- Earning Date
- PRAX 08-04-2025
- TIXT 08-01-2025
- Dividend Yield
- PRAX N/A
- TIXT N/A
- EPS Growth
- PRAX N/A
- TIXT N/A
- EPS
- PRAX N/A
- TIXT N/A
- Revenue
- PRAX $7,765,000.00
- TIXT $2,718,000,000.00
- Revenue This Year
- PRAX N/A
- TIXT $4.29
- Revenue Next Year
- PRAX $3,567.38
- TIXT $3.32
- P/E Ratio
- PRAX N/A
- TIXT N/A
- Revenue Growth
- PRAX 338.45
- TIXT 2.03
- 52 Week Low
- PRAX $26.70
- TIXT $2.13
- 52 Week High
- PRAX $91.83
- TIXT $4.60
- Technical
- Relative Strength Index (RSI)
- PRAX 42.83
- TIXT 52.90
- Support Level
- PRAX $44.25
- TIXT $3.81
- Resistance Level
- PRAX $49.97
- TIXT $4.04
- Average True Range (ATR)
- PRAX 3.36
- TIXT 0.13
- MACD
- PRAX -0.89
- TIXT -0.01
- Stochastic Oscillator
- PRAX 18.84
- TIXT 60.20
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About TIXT TELUS International (Cda) Inc. Subordinate Voting Shares
TELUS International (Cda) Inc is a digital customer experience innovator that designs, builds, and delivers next-generation solutions. Its clients include companies across several verticals, including Tech and Games, eCommerce and FinTech, Banking, Financial Services and Insurance, Communications and Media, and Healthcare. The solutions offered by the company include Digital Experience, Customer Experience, Advisory Services, and Back Office and Automation among other services. Geographically, it derives a majority of its revenue from the European region.